Metadonijev Klorid Alkaloid-Int (Methadone Hydrochloride)

Methadone Hydrochloride is used in opioid‑related pathways for dependence management and long‑term pain control.

• Opioid dependence (maintenance therapy): stabilizes opioid receptors, reduces cravings and withdrawal symptoms in individuals undergoing maintenance treatment.
• Opioid dependence (detoxification): facilitates gradual tapering of opioid use during supervised detox programs.
• Severe chronic pain: provides long‑acting analgesia for patients with persistent pain unresponsive to other opioids.

• Methadone Hydrochloride acts as a full agonist at the µ‑opioid receptor, producing analgesia and suppressing withdrawal by activating the same receptors targeted by endogenous opioids. In addition, it antagonizes N‑methyl‑D‑aspartate (NMDA) receptors and inhibits the reuptake of serotonin and norepinephrine, contributing to its efficacy in chronic pain and reducing tolerance development. These combined actions result in a prolonged half‑life that supports once‑daily dosing in maintenance regimens.

Methadone Hydrochloride may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset often occurring at treatment initiation.
• Constipation: reduced bowel movements that may require dietary or pharmacologic management.
• Dizziness: transient light‑headedness, especially when standing quickly.
• Sweating: increased perspiration, commonly observed during dose adjustments.

Serious or Rare Side Effects

• Respiratory depression: slowed breathing that can be life‑threatening, particularly with overdose or concurrent depressants.
• QT interval prolongation: cardiac electrical changes that may predispose to arrhythmias.
• Anaphylaxis: severe allergic reaction with hives, swelling, and airway compromise.

When prescribing Methadone Hydrochloride, clinicians should observe several safety considerations.

• Assess patient history: evaluate prior opioid use, respiratory disorders, and cardiac conditions before initiation.
• Initiate low dose: start with the lowest effective dose and titrate slowly to minimize overdose risk.
• Monitor cardiac function: obtain baseline ECG and repeat if dose exceeds 100 mg/day or if risk factors exist.
• Avoid concurrent CNS depressants: limit use of benzodiazepines, alcohol, or other opioids to reduce respiratory depression.
• Educate patients: inform about signs of overdose, proper storage, and the importance of adherence.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Methadone Hydrochloride can interact with several medications, altering its plasma levels or enhancing adverse effects.

Major Interactions (Avoid)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase methadone concentrations, raising overdose risk.
• CNS depressants (e.g., benzodiazepines, barbiturates): combined use can cause profound respiratory depression.
• QT‑prolonging drugs (e.g., haloperidol, sotalol): additive effect on cardiac repolarization leading to arrhythmias.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce methadone levels, risking withdrawal.
• Antidepressants (e.g., SSRIs, SNRIs): can affect methadone metabolism and serotonin levels.
• Herbal supplements (e.g., St. John’s wort): may lower drug exposure and diminish therapeutic effect.